Sun Jin Sym

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu et al. · The Lancet Oncology · 2022 · 768 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park et al. · The Lancet Oncology · 2020 · 190 citations

Medicine, Oncology, Pharmacology +16

A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer

Hee Kyung Ahn, Minkyu Jung, Sun Jin Sym et al. · Cancer Chemotherapy and Pharmacology · 2014 · 177 citations · Full text

Medicine, Oncology, Pharmacology +12

Brain metastases in breast cancer: prognostic factors and management

Sung Sook Lee, Jin‐Hee Ahn, Min Kyoung Kim et al. · Breast Cancer Research and Treatment · 2007 · 156 citations

Medicine, Oncology, Surgery +16

LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study

Narikazu Boku, M.-H. Ryu, D-Y. Oh et al. · Annals of Oncology · 2020 · 124 citations

Medicine, Oncology, Pharmacotherapy +15